Abstract
In Chinese medicine, Zheng-hou, instead of disease, is used to define complex medical problems in clinical practice. In the postgenomics era, it becomes particularly compelling to review the application of Zheng-hou in characterizing complex clinical problems independent of disease or syndrome. While disease or syndrome describes a pathological phenotype or phenotypes, Zheng-hou spells the pathological phenome. Clinical Zheng-hou pharmacology (CZP) is an emerging clinical discipline that aims to leverage breakthroughs in the genome-wide solutions for complex medical problems through a combination of the current “omics” technology and the knowledge of Chinese medicine. The concept of CZP suggests that systematic and standard studies of multiple phenotypes will be important because of the collaborative cross between diversified external and internal factors at different levels both in vitro and in vivo. In this paper, we discuss the novel phenomic approaches to the understanding of Zheng-hou and the link of pharmacogenomics to personalized medicine through CZP, or pharmacophenomics. CZP enables ever-finer mapping of Zheng-hou and detection of dynamic variations in most current omics platforms. Although major challenges still remain in identifying and effectively investigating the diversity of Zheng-hou, CZP is expected to pave new paths to the systemic understanding of medical problems. While still at early stages in the clinical phenome domain, there remains great promise that CZP can help us realize the application of personalized medicine and contribute to rational holistic diagnosis and treatment.
Keywords: Chinese medicine, Zheng-hou, Clinical Zheng-hou pharmacology, pharmacogenomics, personalized medicine, phenomic.
Current Vascular Pharmacology
Title:Clinical Zheng-hou Pharmacology: the Missing Link between Pharmacogenomics and Personalized Medicine?
Volume: 13 Issue: 4
Author(s): Ya-Nan Yu, Jun Liu, Lei Zhang, Zhong Wang, Dayue Darrel Duan and Yong-Yan Wang
Affiliation:
Keywords: Chinese medicine, Zheng-hou, Clinical Zheng-hou pharmacology, pharmacogenomics, personalized medicine, phenomic.
Abstract: In Chinese medicine, Zheng-hou, instead of disease, is used to define complex medical problems in clinical practice. In the postgenomics era, it becomes particularly compelling to review the application of Zheng-hou in characterizing complex clinical problems independent of disease or syndrome. While disease or syndrome describes a pathological phenotype or phenotypes, Zheng-hou spells the pathological phenome. Clinical Zheng-hou pharmacology (CZP) is an emerging clinical discipline that aims to leverage breakthroughs in the genome-wide solutions for complex medical problems through a combination of the current “omics” technology and the knowledge of Chinese medicine. The concept of CZP suggests that systematic and standard studies of multiple phenotypes will be important because of the collaborative cross between diversified external and internal factors at different levels both in vitro and in vivo. In this paper, we discuss the novel phenomic approaches to the understanding of Zheng-hou and the link of pharmacogenomics to personalized medicine through CZP, or pharmacophenomics. CZP enables ever-finer mapping of Zheng-hou and detection of dynamic variations in most current omics platforms. Although major challenges still remain in identifying and effectively investigating the diversity of Zheng-hou, CZP is expected to pave new paths to the systemic understanding of medical problems. While still at early stages in the clinical phenome domain, there remains great promise that CZP can help us realize the application of personalized medicine and contribute to rational holistic diagnosis and treatment.
Export Options
About this article
Cite this article as:
Yu Ya-Nan, Liu Jun, Zhang Lei, Wang Zhong, Duan Darrel Dayue and Wang Yong-Yan, Clinical Zheng-hou Pharmacology: the Missing Link between Pharmacogenomics and Personalized Medicine? , Current Vascular Pharmacology 2015; 13 (4) . https://dx.doi.org/10.2174/1570161112666141014144431
DOI https://dx.doi.org/10.2174/1570161112666141014144431 |
Print ISSN 1570-1611 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6212 |
Call for Papers in Thematic Issues
Ischemic Cardiovascular Diseases: Mechanisms, Diagnosis and Therapy
Ischemic cardiovascular disease includes myocardial infarction, coronary atherosclerotic heart disease, angina pectoris, etc., constitute the leading cause of patient mortality by preventing tissues from getting sufficient oxygen and nutrients. Ischemic heart disease, as a clinical condition, is characterized by myocardial ischemia, causing an imbalance between myocardial blood supply and demand, ...read more
TREATMENT OF CARDIOVASCULAR DISEASE IN CHRONIC AND END STAGE KIDNEY DISEASE
Cardiovascular disease still remains the leading cause of death in Chronic and End Stage Kidney Disease, accounting for more than half of all deaths in dialysis patients. During the past decade, research has been focused on novel therapeutic agents that might delay or even reverse cardiovascular disease and vascular calcification, ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Erratum
Current Cardiology Reviews Editorial (Thematic Issue: Current Topics in Sepsis)
Cardiovascular & Hematological Disorders-Drug Targets Atrial Fibrillation – New Frontiers in Anticoagulation
Cardiovascular & Hematological Disorders-Drug Targets A Case of Heavy Proteinuric Non-IgA Mesangial Proliferative Glomerulonephritis Ameliorated by Chinese Herbal Medicines
Current Traditional Medicine subject Index To Volume 2
Current Drug Targets - Cardiovascular & Hematological Disorders Patent Selections:
Recent Patents on Cardiovascular Drug Discovery Adverse Drug Reactions and Safety Considerations of NSAIDs: Clinical Analysis
Current Drug Safety Crocin Protects Against Beta-Amyloid Peptide-Induced Apoptosis in PC12 Cells Via the PI3 K Pathway
Current Molecular Pharmacology Admission, 24 Hours and Discharge Troponin T Among Acute Myocardial Infarction Patients: Differing by Prognostic Contribution
Recent Patents on Biomarkers Does the Immune System Regulate Mood to Defend against Infection? Evidence from Studies of Immune Factors, Depression, and Antidepressants
Current Psychiatry Reviews Recent Advances in Transcatheter Aortic Valve Implantation: Novel Devices and Potential Shortcomings
Current Cardiology Reviews Depression Related Pathophysiologies Relevant in Heart Disease: Insights into the Mechanism Based on Pharmacological Treatments
Current Cardiology Reviews The Impact of Methodology and Confounding Variables on the Association Between Major Depression and Coronary Heart Disease: Review and Recommendations
Current Psychiatry Reviews The Influence of Inflammatory Cytokines on the Proliferation and Osteoblastic Differentiation of MSCs
Current Stem Cell Research & Therapy Polymorphism Gln27Glu of β2 Adrenergic Receptors in Patients with Ischaemic Cardiomyopathy
Current Vascular Pharmacology Humanized Cobra Venom Factor: Experimental Therapeutics for Targeted Complement Activation and Complement Depletion
Current Pharmaceutical Design Non-canonical Molecular Targets for Novel Analgesics: Intracellular Calcium and HCN Channels
Current Neuropharmacology Synthesis and Biological Study of 3-Butyl-1-(2,6-dichlorophenyl)-1H-[1,2,4]triazol- 5(4H)-one Derivatives as Anti-hypertension Drugs
Letters in Drug Design & Discovery Cocaine and HIV-1 Interplay in CNS: Cellular and Molecular Mechanisms
Current HIV Research Neuroprotection of Dietary Virgin Olive Oil on Brain Lipidomics During Stroke
Current Neurovascular Research